How Brazil's courts became the final arbiter of medical treatment in a legal epidemic with profound implications for healthcare equity
Imagine a family facing a rare disease. The public healthcare system doesn't offer the only medication that might help, and time is running out. Their last resort? A lawsuit against the government. This scenario plays out thousands of times daily across Brazil, in a phenomenon known as health judicialization—where courts become the final arbiter of medical treatment. What begins as an individual quest for survival has spawned a legal epidemic that now threatens the very foundations of healthcare for millions.
Health-related lawsuits decided in 2024
Health lawsuits still pending
This article explores how Brazil became entangled in this complex web where law, medicine, and public policy collide, and examines the search for solutions that balance hope with science, and individual rights with collective needs 1 .
Health judicialization occurs when patients bypass administrative health systems to seek treatments, medications, or procedures through court orders. While this pathway can be legitimate when the system fails, it has grown into a structural feature of Brazil's healthcare landscape rather than an exception 1 .
These numbers reveal a profound transformation: the judiciary has effectively become a permanent actor in health policy, making decisions that directly impact medical care, resource allocation, and public health planning 1 .
In September 2024, Brazil's Supreme Court (STF) reached a landmark decision that significantly reshaped the boundaries of health judicialization. The case involved a patient seeking sildenafil citrate (commonly known as Viagra) that hadn't been incorporated into the SUS system, though interestingly, the medication was added to SUS coverage during the proceedings 1 .
The Court established a rigorous new framework that emphasizes deference to technical bodies like CONITEC, recognizing that incorporating health technologies involves complex economic and technical criteria requiring administrative expertise 1 .
The ruling established a clear general prohibition but carved out a limited exception pathway with six cumulative requirements for truly exceptional cases 1 .
| Requirement | Description | Purpose |
|---|---|---|
| Formal Administrative Denial | Official refusal from the health system | Exhaust administrative remedies first |
| Illegal or Unreasonable Delay | Unjustified slowdown in evaluation | Prevent bureaucratic obstruction |
| No SUS Substitute | Treatment unavailable through regular channels | Ensure necessity of requested treatment |
| Scientific Evidence | High-quality proof of safety and efficacy | Base decisions on robust science |
| Clinical Indispensability | Essential for the specific patient | Prevent unnecessary treatments |
| Patient Financial Need | Demonstrated inability to pay | Protect vulnerable populations |
This decision represents a deliberate shift toward what legal scholars call "judicial self-restraint"—where courts acknowledge the limits of their expertise in highly technical domains. The ruling demands that judicial decisions be grounded in qualified technical rationale rather than solely individual medical prescriptions, requiring judges to consult specialized technical opinions from sources like NATJUS 1 .
The financial consequences of health judicialization are staggering, creating what experts describe as a "billion-dollar drain" on Brazil's healthcare resources. Recent research from the Institute of Applied Economic Research (IPEA) reveals that judicialized medications consumed nearly 33% of state pharmaceutical budgets in 2023, while municipalities spent 8.4% of their drug budgets on court-ordered treatments 4 .
This massive reallocation of resources creates a distorting effect on the entire healthcare system. When significant portions of limited budgets are redirected to court-mandated treatments, the result can be shortages of basic medications and reduced capacity for preventive care programs 4 . The problem is nationwide, affecting 100% of participating states in the IPEA study and 58.7% of municipalities 4 .
| Government Level | % of Medication Budget Spent on Judicialized Drugs (2023) | % of Entities Affected | Regional Variation |
|---|---|---|---|
| States | 32.9% | 100% | Not specified |
| Municipalities | 8.4% | 58.7% | Center-West: 80.5% Southeast: 73.3% South: 57.6% Northeast: 46.3% North: 49% |
The financial impact extends beyond the public system. In the private sector, a recent STJ decision held health plans "subsidiarily responsible" for treatments even when not included in ANS coverage lists, creating regulatory uncertainty and potentially driving up costs for all beneficiaries 3 . This mutualization of risk, fundamental to insurance models, becomes threatened when courts introduce unpredictable liabilities, potentially making coverage more expensive and less accessible for the population 3 .
The fosfoetanolamina case represents what we might call a natural experiment in health judicialization—an unplanned situation that nonetheless yielded crucial insights about the dangers of bypassing scientific protocols. Popularly known as the "cancer pill," this synthetic substance became the center of a massive judicialization movement despite lacking both ANVISA approval and robust clinical trials 2 .
A single research institution began distributing the substance without regulatory approval, generating media attention and patient demand 2 .
Under public pressure, lawmakers passed legislation authorizing use before technical evaluation was complete 2 .
Patients across Brazil successfully sued for access, based on hope and testimonials rather than evidence 2 .
The STF eventually declared the authorization law unconstitutional, citing the separation of powers and the need for scientific validation 2 .
Subsequent rigorous clinical trials demonstrated the substance's ineffectiveness, confirming it offered false hope while potentially diverting patients from proven treatments 2 .
"The hope that society places in medications, especially those intended to treat diseases such as cancer, cannot distance itself from science."
This case revealed several critical aspects of health judicialization. It demonstrated how emotional appeals and public pressure can short-circuit evidence-based decision making. It also highlighted the risks when courts, despite good intentions, become vehicles for unproven treatments. Most importantly, it showed that judicialization can actually harm patients by promoting therapeutically ineffective options while delaying or displacing established, beneficial treatments 2 .
As Brazil grapples with health judicialization, researchers, medical professionals, and legal experts have developed what we might call a "toolkit" of approaches to manage the phenomenon. These tools aim to balance individual rights with systemic sustainability, combining technical resources with institutional reforms.
Provide judges with specialized scientific input to inform their decisions, helping distinguish between validated therapies and those lacking robust support 2 .
Extrajudicial mechanisms for providing non-incorporated medications indicate a promising trend toward preventive conflict resolution 4 .
Initiatives that create rare spaces where medical professionals, judges, managers, and regulators can develop shared understanding 2 .
Looking globally provides valuable perspective on how independent technical bodies can create evidence-based treatment guidelines 3 .
| Tool/Initiative | Function | Example/Outcome |
|---|---|---|
| NATJUS Technical Advisory | Provides judges with scientific evidence | Differentiates evidence-based from experimental treatments |
| Administrative Resolution Channels | Provides non-incorporated drugs without litigation | 52.1% of municipalities use this to avoid lawsuits |
| Collaborative Dialogues | Unites health and justice stakeholders | Project Quero-Quero eliminated surgery lawsuits at SOS Cardio |
| International Models | Offers evidence-based coverage frameworks | UK's NICE and France's Haute Autorité de Santé |
| Judicial Training | Enhances technical understanding of health evaluation | Fonajus initiatives through CNJ |
Health judicialization in Brazil represents a profound challenge at the intersection of human rights, medical science, and public resource management.
The phenomenon emerges from understandable human impulses—the fight for survival, the hope for healing—but has grown to threaten the equity and sustainability of the healthcare system itself.
The recent trajectory, particularly the 2024 STF decision, signals a necessary maturation in Brazil's approach. By establishing strict evidentiary requirements for exceptional cases while generally deferring to technical bodies on incorporation decisions, the Court has charted a middle path that respects both constitutional rights and institutional expertise. As Minister Luís Roberto Barroso's opinion emphasized, the protection of fundamental rights cannot be achieved through atomized decisions that undermine systemic equity 1 .
Continued commitment to "procedural integrity"—robust evaluation processes that earn public trust, transparent decision-making that demonstrates rational allocation, and ongoing dialogue between the health and justice sectors.
"Our proposal is not to combat judicialization, but its trivialization—ensuring that it remains a legitimate instrument for correcting system failures, and not an institutionalized shortcut" 2 .
In navigating this delicate balance, Brazil faces a question that resonates across health systems worldwide: how to preserve both compassion and reason, both individual hope and collective wisdom, in the ongoing pursuit of health for all.